Literature DB >> 26466836

Graves' ophthalmopathy treated with protracted hypofractionated low-dose adaptive radiotherapy: case report and review of the literature.

Ozan Cem Guler1, Cem Onal2, Gungor Arslan1.   

Abstract

Graves' ophthalmopathy (GO) is the most common extra-thyroidal manifestation of Graves' disease. The treatment options for GO are high-dose glucocorticoids, selenium, rituximab, cyclosporine, orbital radiotherapy (RT), and surgery. A 43-year-old male patient was referred to our clinic with complaints of severe bilateral proptosis, diplopia, and orbital pain at both globes for 1 year. Pretreatment magnetic resonance imaging revealed bilateral proptosis, the expansion of bilateral optic nerves sheath, the increase of right medial muscle thickness, and a mass at the right eyehole. Patient was treated with 1 Gy per fraction per week with a total dose of 10 Gy over 10 weeks with adoptive intensity-modulated radiotherapy technique. During RT at 3rd and 6th weeks, a moderate shrinkage of the lesions was observed. The patient has been disease free, has had no complaints for 36 months, and has not required any surgical intervention. No late side effects such as retinopathy or cataract were observed. Orbital RT with innovative techniques may be considered as an initial local treatment for GO. With adoptive protracted low dose RT, a good clinical and radiological response could be seen without increasing early and late reactions.

Entities:  

Keywords:  Graves’ disease; Ophthalmopathy; Radiotherapy

Mesh:

Year:  2015        PMID: 26466836     DOI: 10.1007/s00508-015-0870-z

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  17 in total

1.  Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial.

Authors:  G J Kahaly; H P Rösler; S Pitz; G Hommel
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

Review 2.  Consensus guidelines for radiation therapy of benign diseases: a multicenter approach in Germany.

Authors:  Oliver Micke; M Heinrich Seegenschmiedt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

Review 3.  Orbital radiotherapy for thyroid eye disease.

Authors:  Peter J Dolman; Suryasnata Rath
Journal:  Curr Opin Ophthalmol       Date:  2012-09       Impact factor: 3.761

4.  The efficacy of radiation therapy in the treatment of Graves' orbitopathy.

Authors:  Chance Matthiesen; J Spencer Thompson; David Thompson; Bradley Farris; Byron Wilkes; Salahuddin Ahmad; Terence Herman; Carl Bogardus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-27       Impact factor: 7.038

5.  Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.

Authors:  Marius N Stan; James A Garrity; Elizabeth A Bradley; John J Woog; Mark M Bahn; Michael D Brennan; Sandra C Bryant; Sara J Achenbach; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2006-09-19       Impact factor: 5.958

6.  Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.

Authors:  A Jane Dickinson; Bijay Vaidya; Margaret Miller; Alan Coulthard; Petros Perros; Elizabeth Baister; Christopher D Andrews; Lutz Hesse; Johannes T Heverhagen; Armin E Heufelder; Pat Kendall-Taylor
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

7.  Proptosis in dysthyroid ophthalmopathy: a case series of 10,931 Japanese cases.

Authors:  Ai Kozaki; Rishu Inoue; Noriko Komoto; Toshine Maeda; Yoichi Inoue; Toshu Inoue; Masahiko Ayaki
Journal:  Optom Vis Sci       Date:  2010-03       Impact factor: 1.973

8.  Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.

Authors:  L Tallstedt; G Lundell; O Tørring; G Wallin; J G Ljunggren; H Blomgren; A Taube
Journal:  N Engl J Med       Date:  1992-06-25       Impact factor: 91.245

9.  The relation of Graves' ophthalmopathy to circulating thyroid hormone status.

Authors:  J M Kim; L LaBree; L Levin; S E Feldon
Journal:  Br J Ophthalmol       Date:  2004-01       Impact factor: 4.638

10.  Outcome of thyroid associated ophthalmopathy treated by radiation therapy.

Authors:  Mirna Abboud; Asma Arabi; Ibrahim Salti; Fady Geara
Journal:  Radiat Oncol       Date:  2011-05-13       Impact factor: 3.481

View more
  3 in total

1.  Longer treatment time and lower radiation doses-an alternative for Graves' ophthalmopathy treatment.

Authors:  Cem Onal; Ozan Cem Guler
Journal:  Strahlenther Onkol       Date:  2021-10-01       Impact factor: 4.033

2.  Reply to: Longer treatment time and lower radiation doses-an alternative for Graves' ophthalmopathy treatment.

Authors:  Thomas Weissmann; Florian Putz; Benjamin Frey
Journal:  Strahlenther Onkol       Date:  2022-04-25       Impact factor: 4.033

3.  The Clinical Features of Graves' Orbitopathy with Elevated Intraocular Pressure.

Authors:  Shu-Xian Fan; Peng Zeng; Zi-Jing Li; Jing Wang; Jia-Qi Liang; Yun-Ru Liao; Yu-Xin Hu; Ming-Tong Xu; Mei Wang
Journal:  J Ophthalmol       Date:  2021-01-25       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.